The World of Dementia Beyond 2020
Identifieur interne : 000985 ( Istex/Corpus ); précédent : 000984; suivant : 000986The World of Dementia Beyond 2020
Auteurs : Henry Brodaty ; Monique M. B. Breteler ; Steven T. Dekosky ; Pascale Dorenlot ; Laura Fratiglioni ; Christoph Hock ; Paul-Ariel Kenigsberg ; Philip Scheltens ; Bart De StrooperSource :
- Journal of the American Geriatrics Society [ 0002-8614 ] ; 2011-05.
English descriptors
- KwdEn :
- Adverse effects, Alzheimer, Alzheimer disease, Alzheimers dement, Amyloid, Amyloid pathway, Amyloid precursor protein, Apoe, Clinical effect phase, Clinical trials, Consulting fees, Current phase, Dementia, Dementia prevalence, Deposition inhibitor, Diabetes mellitus, Dire projections, Drug development, Drug therapies, Fondation, Fondation mederic alzheimer, Global burden, Glycogen synthase, Henry brodaty, Immunization, Immunotherapy, Inhibitor, Lancet neurol, Late life, Literature searches, Medical research council, Molecular biology, Nancial relationships, Nerve growth factor, Neurimmune therapeutics, Neuropathology group, Oligomer aggregation, Passive immunotherapy, Peptide, Pharmaceutical industry, Pparg stimulant, Protective factors, Protein antibody, Receptor, Research centre, Societal costs, Study phase, Synthesis inhibitor, Vascular risk factors.
- Teeft :
- Adverse effects, Alzheimer, Alzheimer disease, Alzheimers dement, Amyloid, Amyloid pathway, Amyloid precursor protein, Apoe, Clinical effect phase, Clinical trials, Consulting fees, Current phase, Dementia, Dementia prevalence, Deposition inhibitor, Diabetes mellitus, Dire projections, Drug development, Drug therapies, Fondation, Fondation mederic alzheimer, Global burden, Glycogen synthase, Henry brodaty, Immunization, Immunotherapy, Inhibitor, Lancet neurol, Late life, Literature searches, Medical research council, Molecular biology, Nancial relationships, Nerve growth factor, Neurimmune therapeutics, Neuropathology group, Oligomer aggregation, Passive immunotherapy, Peptide, Pharmaceutical industry, Pparg stimulant, Protective factors, Protein antibody, Receptor, Research centre, Societal costs, Study phase, Synthesis inhibitor, Vascular risk factors.
Abstract
Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments—mainly targeting the amyloid pathway, tau protein, and immunotherapy—that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia‐modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.
Url:
DOI: 10.1111/j.1532-5415.2011.03365.x
Links to Exploration step
ISTEX:3532435BFD3EF646FC74FD62B25CB9AE4AC6283FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The World of Dementia Beyond 2020</title><author><name sortKey="Brodaty, Henry" sort="Brodaty, Henry" uniqKey="Brodaty H" first="Henry" last="Brodaty">Henry Brodaty</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Breteler, Monique M B" sort="Breteler, Monique M B" uniqKey="Breteler M" first="Monique M. B." last="Breteler">Monique M. B. Breteler</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Dekosky, Steven T" sort="Dekosky, Steven T" uniqKey="Dekosky S" first="Steven T." last="Dekosky">Steven T. Dekosky</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Dorenlot, Pascale" sort="Dorenlot, Pascale" uniqKey="Dorenlot P" first="Pascale" last="Dorenlot">Pascale Dorenlot</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Fratiglioni, Laura" sort="Fratiglioni, Laura" uniqKey="Fratiglioni L" first="Laura" last="Fratiglioni">Laura Fratiglioni</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Hock, Christoph" sort="Hock, Christoph" uniqKey="Hock C" first="Christoph" last="Hock">Christoph Hock</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Kenigsberg, Paul Riel" sort="Kenigsberg, Paul Riel" uniqKey="Kenigsberg P" first="Paul-Ariel" last="Kenigsberg">Paul-Ariel Kenigsberg</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Scheltens, Philip" sort="Scheltens, Philip" uniqKey="Scheltens P" first="Philip" last="Scheltens">Philip Scheltens</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="De Strooper, Bart" sort="De Strooper, Bart" uniqKey="De Strooper B" first="Bart" last="De Strooper">Bart De Strooper</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3532435BFD3EF646FC74FD62B25CB9AE4AC6283F</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1532-5415.2011.03365.x</idno><idno type="url">https://api.istex.fr/document/3532435BFD3EF646FC74FD62B25CB9AE4AC6283F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000985</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000985</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The World of Dementia Beyond 2020</title><author><name sortKey="Brodaty, Henry" sort="Brodaty, Henry" uniqKey="Brodaty H" first="Henry" last="Brodaty">Henry Brodaty</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Breteler, Monique M B" sort="Breteler, Monique M B" uniqKey="Breteler M" first="Monique M. B." last="Breteler">Monique M. B. Breteler</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Dekosky, Steven T" sort="Dekosky, Steven T" uniqKey="Dekosky S" first="Steven T." last="Dekosky">Steven T. Dekosky</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Dorenlot, Pascale" sort="Dorenlot, Pascale" uniqKey="Dorenlot P" first="Pascale" last="Dorenlot">Pascale Dorenlot</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Fratiglioni, Laura" sort="Fratiglioni, Laura" uniqKey="Fratiglioni L" first="Laura" last="Fratiglioni">Laura Fratiglioni</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Hock, Christoph" sort="Hock, Christoph" uniqKey="Hock C" first="Christoph" last="Hock">Christoph Hock</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Kenigsberg, Paul Riel" sort="Kenigsberg, Paul Riel" uniqKey="Kenigsberg P" first="Paul-Ariel" last="Kenigsberg">Paul-Ariel Kenigsberg</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="Scheltens, Philip" sort="Scheltens, Philip" uniqKey="Scheltens P" first="Philip" last="Scheltens">Philip Scheltens</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author><author><name sortKey="De Strooper, Bart" sort="De Strooper, Bart" uniqKey="De Strooper B" first="Bart" last="De Strooper">Bart De Strooper</name><affiliation><mods:affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of the American Geriatrics Society</title><title level="j" type="alt">JOURNAL OF AMERICAN GERIATRICS SOCIETY</title><idno type="ISSN">0002-8614</idno><idno type="eISSN">1532-5415</idno><imprint><biblScope unit="vol">59</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="923">923</biblScope><biblScope unit="page" to="927">927</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-05">2011-05</date></imprint><idno type="ISSN">0002-8614</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-8614</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse effects</term><term>Alzheimer</term><term>Alzheimer disease</term><term>Alzheimers dement</term><term>Amyloid</term><term>Amyloid pathway</term><term>Amyloid precursor protein</term><term>Apoe</term><term>Clinical effect phase</term><term>Clinical trials</term><term>Consulting fees</term><term>Current phase</term><term>Dementia</term><term>Dementia prevalence</term><term>Deposition inhibitor</term><term>Diabetes mellitus</term><term>Dire projections</term><term>Drug development</term><term>Drug therapies</term><term>Fondation</term><term>Fondation mederic alzheimer</term><term>Global burden</term><term>Glycogen synthase</term><term>Henry brodaty</term><term>Immunization</term><term>Immunotherapy</term><term>Inhibitor</term><term>Lancet neurol</term><term>Late life</term><term>Literature searches</term><term>Medical research council</term><term>Molecular biology</term><term>Nancial relationships</term><term>Nerve growth factor</term><term>Neurimmune therapeutics</term><term>Neuropathology group</term><term>Oligomer aggregation</term><term>Passive immunotherapy</term><term>Peptide</term><term>Pharmaceutical industry</term><term>Pparg stimulant</term><term>Protective factors</term><term>Protein antibody</term><term>Receptor</term><term>Research centre</term><term>Societal costs</term><term>Study phase</term><term>Synthesis inhibitor</term><term>Vascular risk factors</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adverse effects</term><term>Alzheimer</term><term>Alzheimer disease</term><term>Alzheimers dement</term><term>Amyloid</term><term>Amyloid pathway</term><term>Amyloid precursor protein</term><term>Apoe</term><term>Clinical effect phase</term><term>Clinical trials</term><term>Consulting fees</term><term>Current phase</term><term>Dementia</term><term>Dementia prevalence</term><term>Deposition inhibitor</term><term>Diabetes mellitus</term><term>Dire projections</term><term>Drug development</term><term>Drug therapies</term><term>Fondation</term><term>Fondation mederic alzheimer</term><term>Global burden</term><term>Glycogen synthase</term><term>Henry brodaty</term><term>Immunization</term><term>Immunotherapy</term><term>Inhibitor</term><term>Lancet neurol</term><term>Late life</term><term>Literature searches</term><term>Medical research council</term><term>Molecular biology</term><term>Nancial relationships</term><term>Nerve growth factor</term><term>Neurimmune therapeutics</term><term>Neuropathology group</term><term>Oligomer aggregation</term><term>Passive immunotherapy</term><term>Peptide</term><term>Pharmaceutical industry</term><term>Pparg stimulant</term><term>Protective factors</term><term>Protein antibody</term><term>Receptor</term><term>Research centre</term><term>Societal costs</term><term>Study phase</term><term>Synthesis inhibitor</term><term>Vascular risk factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments—mainly targeting the amyloid pathway, tau protein, and immunotherapy—that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia‐modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>dementia</json:string><json:string>amyloid</json:string><json:string>alzheimer</json:string><json:string>immunotherapy</json:string><json:string>receptor</json:string><json:string>apoe</json:string><json:string>fondation</json:string><json:string>fondation mederic alzheimer</json:string><json:string>inhibitor</json:string><json:string>peptide</json:string><json:string>immunization</json:string><json:string>protein antibody</json:string><json:string>protective factors</json:string><json:string>passive immunotherapy</json:string><json:string>amyloid precursor protein</json:string><json:string>clinical trials</json:string><json:string>adverse effects</json:string><json:string>lancet neurol</json:string><json:string>clinical effect phase</json:string><json:string>deposition inhibitor</json:string><json:string>current phase</json:string><json:string>molecular biology</json:string><json:string>research centre</json:string><json:string>oligomer aggregation</json:string><json:string>henry brodaty</json:string><json:string>diabetes mellitus</json:string><json:string>study phase</json:string><json:string>dire projections</json:string><json:string>dementia prevalence</json:string><json:string>drug therapies</json:string><json:string>glycogen synthase</json:string><json:string>nerve growth factor</json:string><json:string>amyloid pathway</json:string><json:string>synthesis inhibitor</json:string><json:string>late life</json:string><json:string>pharmaceutical industry</json:string><json:string>societal costs</json:string><json:string>global burden</json:string><json:string>consulting fees</json:string><json:string>nancial relationships</json:string><json:string>neurimmune therapeutics</json:string><json:string>literature searches</json:string><json:string>drug development</json:string><json:string>alzheimer disease</json:string><json:string>pparg stimulant</json:string><json:string>vascular risk factors</json:string><json:string>alzheimers dement</json:string><json:string>neuropathology group</json:string><json:string>medical research council</json:string></teeft></keywords><author><json:item><name>Henry Brodaty MD, DSc</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item><json:item><name>Monique M. B. Breteler MD, PhD</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item><json:item><name>Steven T. DeKosky MD</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item><json:item><name>Pascale Dorenlot MD, PhD</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item><json:item><name>Laura Fratiglioni MD, PhD</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item><json:item><name>Christoph Hock MD</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item><json:item><name>Paul‐Ariel Kenigsberg PhD</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item><json:item><name>Philip Scheltens MD, PhD</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item><json:item><name>Bart De Strooper MD, PhD</name><affiliations><json:string>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Alzheimer's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>research</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>diagnosis</value></json:item></subject><articleId><json:string>JGS3365</json:string></articleId><arkIstex>ark:/67375/WNG-WF6PC687-V</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments—mainly targeting the amyloid pathway, tau protein, and immunotherapy—that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia‐modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.</abstract><qualityIndicators><score>6.937</score><pdfWordCount>3029</pdfWordCount><pdfCharCount>21538</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>159</abstractWordCount><abstractCharCount>1097</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>The World of Dementia Beyond 2020</title><pmid><json:string>21488846</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Journal of the American Geriatrics Society</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1532-5415</json:string></doi><issn><json:string>0002-8614</json:string></issn><eissn><json:string>1532-5415</json:string></eissn><publisherId><json:string>JGS</json:string></publisherId><volume>59</volume><issue>5</issue><pages><first>923</first><last>927</last><total>5</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2011</json:string><json:string>2040</json:string><json:string>2005</json:string><json:string>2001</json:string><json:string>2020</json:string><json:string>2008</json:string></date><geogName><json:string>Midterminal region</json:string></geogName><orgName><json:string>Stockholm Gerontology Research Center, Stockholm, Sweden</json:string><json:string>Department of Neurobiology, Care Sciences and Society</json:string><json:string>World Health Organization.</json:string><json:string>Medical Center, Rotterdam</json:string><json:string>University of Zurich</json:string><json:string>Karolinska Institutet</json:string><json:string>Netherlands, and German Center for Neurodegenerative Diseases</json:string><json:string>American Geriatrics Society W</json:string><json:string>University of Virginia</json:string><json:string>PsychoGenics Inc</json:string><json:string>Erasmus University</json:string><json:string>and Department of Molecular and Developmental Genetics</json:string><json:string>Neuropathology Group.</json:string><json:string>Neurology and Alzheimer Center</json:string><json:string>VU University Medical Center, Amsterdam</json:string><json:string>Foundation, SAO</json:string><json:string>Debiopharm</json:string><json:string>DZNE</json:string><json:string>Division of Psychiatry Research</json:string><json:string>Dementia Collaborative Research Centre, University of New South Wales, Sydney</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Laura Fratiglioni</json:string><json:string>Eli Lilly</json:string><json:string>Bart De Strooper</json:string><json:string>Henry Brodaty</json:string><json:string>Paul-Ariel Kenigsberg</json:string><json:string>Louisa Gibson</json:string><json:string>Pascale Dorenlot</json:string><json:string>Philip Scheltens</json:string><json:string>The</json:string><json:string>M. B. Breteler</json:string><json:string>Steven T. DeKosky</json:string><json:string>Christoph Hock</json:string><json:string>Mederic Alzheimer</json:string><json:string>Disease</json:string></persName><placeName><json:string>Paris</json:string><json:string>Bristol</json:string><json:string>Switzerland</json:string><json:string>Germany</json:string><json:string>Australia</json:string><json:string>Pittsburgh</json:string><json:string>Leuven</json:string><json:string>France</json:string><json:string>Zurich</json:string><json:string>Belgium</json:string><json:string>Netherlands</json:string></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-WF6PC687-V</json:string></ark><categories><wos><json:string>1 - social science</json:string><json:string>2 - gerontology</json:string><json:string>1 - science</json:string><json:string>2 - geriatrics & gerontology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - geriatrics</json:string></scienceMetrix><scopus></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - gynecologie. andrologie. obstetrique</json:string></inist></categories><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1111/j.1532-5415.2011.03365.x</json:string></doi><id>3532435BFD3EF646FC74FD62B25CB9AE4AC6283F</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/3532435BFD3EF646FC74FD62B25CB9AE4AC6283F/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/3532435BFD3EF646FC74FD62B25CB9AE4AC6283F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/3532435BFD3EF646FC74FD62B25CB9AE4AC6283F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">The World of Dementia Beyond 2020</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><availability><licence>© 2011, Copyright the Authors. Journal compilation © 2011, The American Geriatrics Society</licence></availability><date type="published" when="2011-05"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">The World of Dementia Beyond 2020</title><title level="a" type="short">DEMENTIA BEYOND 2020</title><author xml:id="author-0000"><persName><forename type="first">Henry</forename><surname>Brodaty</surname><roleName type="degree">MD, DSc</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Monique M. B.</forename><surname>Breteler</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Steven T.</forename><surname>DeKosky</surname><roleName type="degree">MD</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Pascale</forename><surname>Dorenlot</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Laura</forename><surname>Fratiglioni</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Christoph</forename><surname>Hock</surname><roleName type="degree">MD</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Paul‐Ariel</forename><surname>Kenigsberg</surname><roleName type="degree">PhD</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Philip</forename><surname>Scheltens</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Bart</forename><surname>De Strooper</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.<address><country key="US"></country></address></affiliation></author><idno type="istex">3532435BFD3EF646FC74FD62B25CB9AE4AC6283F</idno><idno type="ark">ark:/67375/WNG-WF6PC687-V</idno><idno type="DOI">10.1111/j.1532-5415.2011.03365.x</idno><idno type="unit">JGS3365</idno><idno type="supplier">3365</idno><idno type="toTypesetVersion">file:JGS.JGS3365.pdf</idno></analytic><monogr><title level="j" type="main">Journal of the American Geriatrics Society</title><title level="j" type="alt">JOURNAL OF AMERICAN GERIATRICS SOCIETY</title><idno type="pISSN">0002-8614</idno><idno type="eISSN">1532-5415</idno><idno type="book-DOI">10.1111/(ISSN)1532-5415</idno><idno type="book-part-DOI">10.1111/jgs.2011.59.issue-5</idno><idno type="product">JGS</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">59</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="923">923</biblScope><biblScope unit="page" to="927">927</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-05"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><p>Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments—mainly targeting the amyloid pathway, tau protein, and immunotherapy—that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia‐modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">dementia</term><term xml:id="k2">Alzheimer's disease</term><term xml:id="k3">research</term><term xml:id="k4">treatment</term><term xml:id="k5">diagnosis</term></keywords><keywords rend="tocHeading1"><term>Special Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/3532435BFD3EF646FC74FD62B25CB9AE4AC6283F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Inc</publisherName><publisherLoc>Malden, USA</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1532-5415</doi><issn type="print">0002-8614</issn><issn type="electronic">1532-5415</issn><idGroup><id type="product" value="JGS"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="JOURNAL OF AMERICAN GERIATRICS SOCIETY">Journal of the American Geriatrics Society</title></titleGroup></publicationMeta><publicationMeta level="part" position="05105"><doi origin="wiley">10.1111/jgs.2011.59.issue-5</doi><numberingGroup><numbering type="journalVolume" number="59">59</numbering><numbering type="journalIssue" number="5">5</numbering></numberingGroup><coverDate startDate="2011-05">May 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="21" status="forIssue"><doi origin="wiley">10.1111/j.1532-5415.2011.03365.x</doi><idGroup><id type="unit" value="JGS3365"></id><id type="supplier" value="3365"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="tocHeading1">Special Articles</title></titleGroup><copyright>© 2011, Copyright the Authors. Journal compilation © 2011, The American Geriatrics Society</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:3.1.6 mode:FullText" date="2012-08-23"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-04-13"></event><event type="publishedOnlineFinalForm" date="2011-05-13"></event><event type="firstOnline" date="2011-04-13"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-31"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="923">923</numbering><numbering type="pageLast" number="927">927</numbering></numberingGroup><correspondenceTo>Address correspondence to Henry Brodaty, Dementia Collaborative Research Centre, University of New South Wales, Sydney 2052, Australia. E‐mail: <email normalForm="h.brodaty@unsw.edu.au">h.brodaty@unsw.edu.au</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JGS.JGS3365.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="23"></count><count type="wordTotal" number="4083"></count><count type="linksCrossRef" number="32"></count></countGroup><titleGroup><title type="main">The World of Dementia Beyond 2020</title><title type="shortAuthors">BRODATY ET AL.</title><title type="short">DEMENTIA BEYOND 2020</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#aff-1-1"><personName><givenNames>Henry</givenNames><familyName>Brodaty</familyName><degrees>MD, DSc</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#aff-1-1"><personName><givenNames>Monique M. B.</givenNames><familyName>Breteler</familyName><degrees>MD, PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#aff-1-1"><personName><givenNames>Steven T.</givenNames><familyName>DeKosky</familyName><degrees>MD</degrees></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#aff-1-1"><personName><givenNames>Pascale</givenNames><familyName>Dorenlot</familyName><degrees>MD, PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#aff-1-1"><personName><givenNames>Laura</givenNames><familyName>Fratiglioni</familyName><degrees>MD, PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#aff-1-1"><personName><givenNames>Christoph</givenNames><familyName>Hock</familyName><degrees>MD</degrees></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#aff-1-1"><personName><givenNames>Paul‐Ariel</givenNames><familyName>Kenigsberg</familyName><degrees>PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#aff-1-1"><personName><givenNames>Philip</givenNames><familyName>Scheltens</familyName><degrees>MD, PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#aff-1-1"><personName><givenNames>Bart</givenNames><familyName>De Strooper</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="US"><unparsedAffiliation>From the
<sup>*</sup>Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; <sup>†</sup>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; <sup>‡</sup>School of Medicine, University of Virginia, Charlottesville, Virginia; <sup>§</sup>Studies Department and <sup>**</sup>Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; <sup>∥</sup>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; <sup>#</sup>Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; <sup>††</sup>Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and <sup>‡‡</sup>Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">dementia</keyword><keyword xml:id="k2">Alzheimer's disease</keyword><keyword xml:id="k3">research</keyword><keyword xml:id="k4">treatment</keyword><keyword xml:id="k5">diagnosis</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments—mainly targeting the amyloid pathway, tau protein, and immunotherapy—that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia‐modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The World of Dementia Beyond 2020</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>DEMENTIA BEYOND 2020</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The World of Dementia Beyond 2020</title></titleInfo><name type="personal"><namePart type="given">Henry</namePart><namePart type="family">Brodaty</namePart><namePart type="termsOfAddress">MD, DSc</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Monique M. B.</namePart><namePart type="family">Breteler</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Steven T.</namePart><namePart type="family">DeKosky</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pascale</namePart><namePart type="family">Dorenlot</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Fratiglioni</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christoph</namePart><namePart type="family">Hock</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul‐Ariel</namePart><namePart type="family">Kenigsberg</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Philip</namePart><namePart type="family">Scheltens</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bart</namePart><namePart type="family">De Strooper</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>From the*Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia; †Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; ‡School of Medicine, University of Virginia, Charlottesville, Virginia; §Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France; ∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; #Division of Psychiatry Research, University of Zürich, Zurich, Switzerland; ††Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands; and ‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Inc</publisher><place><placeTerm type="text">Malden, USA</placeTerm></place><dateIssued encoding="w3cdtf">2011-05</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">1</extent><extent unit="formulas">0</extent><extent unit="references">23</extent><extent unit="linksCrossRef">32</extent><extent unit="words">4083</extent></physicalDescription><abstract lang="en">Counterpoised against dire projections of the tripling of the prevalence of dementia over the next 40 years are major developments in diagnostic biomarkers, neuroimaging, the molecular biology of Alzheimer's disease (AD), epidemiology of risk and protective factors, and drug treatments—mainly targeting the amyloid pathway, tau protein, and immunotherapy—that may have the potential to modify the progression of AD. Drug combinations and presymptomatic treatments are also being investigated. Previous trials of dementia‐modifying drugs have not shown benefit, and even if current Phase III trials prove successful, these drugs will not eradicate other dementias, could (if not curative) increase dementia duration and prevalence, and are unlikely to come onto the market before 2020. In the meantime, delaying the onset of dementia by even 2 years would have significant economic and societal effects. This article provides an overview of current achievements and potentials of basic and clinical research that might affect the development of dementia prevalence and care within the near future.</abstract><subject lang="en"><genre>keywords</genre><topic>dementia</topic><topic>Alzheimer's disease</topic><topic>research</topic><topic>treatment</topic><topic>diagnosis</topic></subject><relatedItem type="host"><titleInfo><title>Journal of the American Geriatrics Society</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0002-8614</identifier><identifier type="eISSN">1532-5415</identifier><identifier type="DOI">10.1111/(ISSN)1532-5415</identifier><identifier type="PublisherID">JGS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>923</start><end>927</end><total>5</total></extent></part></relatedItem><identifier type="istex">3532435BFD3EF646FC74FD62B25CB9AE4AC6283F</identifier><identifier type="ark">ark:/67375/WNG-WF6PC687-V</identifier><identifier type="DOI">10.1111/j.1532-5415.2011.03365.x</identifier><identifier type="ArticleID">JGS3365</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2011, Copyright the Authors. Journal compilation © 2011, The American Geriatrics Society</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Blackwell Publishing Inc</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/3532435BFD3EF646FC74FD62B25CB9AE4AC6283F/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000985 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000985 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:3532435BFD3EF646FC74FD62B25CB9AE4AC6283F
|texte= The World of Dementia Beyond 2020
}}
| This area was generated with Dilib version V0.6.33. |  |